# Parabilis Medicines (PBLS) — Analyst Forecast

PBLS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/pbls/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 5 | 0 | 0 | 5 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Jul 6, 2026 | Leerink Partners | Initiated Coverage | Outperform | $40.00 |
| Jul 6, 2026 | Guggenheim | Initiated Coverage | Buy | $40.00 |
| Jul 6, 2026 | B of A Securities | Initiated Coverage | Buy | $45.00 |

## Frequently Asked Questions

### Is PBLS a buy, sell, or hold?

Analysts covering Parabilis Medicines currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on PBLS?

On Jul 6, 2026, Leerink Partners initiated coverage of Parabilis Medicines at Outperform with a price target of $40.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).